medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Original Article

High Probability of Lynch Syndrome among colorectal cancer patients in Indonesia is associated with higher occurrence of KRAS and PIK3CA mutations

Short title: KRAS/PIK3CA Mutations and Lynch Syndrome CRC
Short authors: Heriyanto et al.

Didik Setyo Heriyanto[a], Naomi Yoshuantari[a], Gilang Akbariani[b], Vincent Lau[a], Hanifa Hanini[b], Zulfa Hidayati[b], Muhammad Zulfikar Arief[b], Andrew Nobiantoro Gunawan[a], Asep Muhamad Ridwanuloh[c], Wien Kusharyoto[c], Adeodatus Yuda Handaya[d], Mohammad Ilyas[e], Johan Kurnianda[f], Susanna Hilda Hutajulu[f], Susanti Susanti[b,e,g]

[a]Department of Anatomical Pathology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr Sardjito General Hospital Yogyakarta, Indonesia
[b]Pathgen Diagnostik Teknologi, Ir. Soekarno Science and Technology Park, National Research and Innovation Agency Republic of Indonesia, Bogor, Indonesia
[c]Research Center for Genetic Engineering, Research Organization for Life Sciences and Environment, National Research and Innovation Agency Republic of Indonesia, Ir. Soekarno Science and Technology Park, Bogor, Indonesia
[d]Division of Digestive Surgeon, Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr Sardjito General Hospital Yogyakarta, Indonesia
[e]Molecular Pathology Research Group, Academic Unit of Translational Medical Science, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, United Kingdom
[f]Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/ Dr Sardjito General Hospital Yogyakarta, Indonesia
[g]Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Muhammadiyah Purwokerto, Indonesia

ORCID
Didik Setyo Heriyanto: https://orcid.org/0000-0001-9728-5046
Naomi Yoshuantari: https://orcid.org/0000-0002-6881-8648
Gilang Akbariani: https://orcid.org/0000-0003-1362-3613
Vincent Lau: https://orcid.org/0000-0003-4698-7501
Hanifa Hanini: https://orcid.org/0009-0001-1434-3210
Zulfa Hidayati: https://orcid.org/0009-0004-1711-815X
Muhammad Zulfikar Arief: https://orcid.org/0009-0004-7277-7705
Andrew Nobiantoro Gunawan: https://orcid.org/0009-0006-0127-7636
Asep Muhamad Ridwanuloh: https://orcid.org/0000-0002-8648-3677
Wien Kusharyoto: https://orcid.org/0000-0003-3959-2691
Adeodatus Yuda Handaya: https://orcid.org/0000-0003-0256-1955
Mohammad Ilyas: https://orcid.org/0000-0001-7949-7504
Johan Kurnianda: https://orcid.org/0000-0002-2045-1795
Susanna Hilda Hutajulu: https://orcid.org/0000-0001-9236-9435
Susanti Susanti: https://orcid.org/0000-0002-6570-7117

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Grant Support

The authors received financial support from the Applied Research Grant 2020–2021, The Indonesian Ministry of Research, Technology, and Higher Education and the Institutional Links grant, ID 527558574, under the Newton Institutional Link-Indonesia KLN Fund partnership, funded by the UK Department for Business, Energy and Industrial Strategy and Indonesia Ministry of Research Technology & Higher Education and delivered by the British Council.

Correspondence

Susanti Susanti, Pathgen Diagnostik Teknologi, Ir. Soekarno Science and Technology Park, National Research and Innovation Agency, Republic of Indonesia, Bogor, 16911 Indonesia.
E-mail: susanti@pathgen.co.id
Telephone number:+447342670309

Financial Disclosures

MI was appointed as specialist committee member to the Diagnostics Assessment Committee of the National Institute for Health and Care Excellence (NICE), which produced the guidance DG27 on Lynch Syndrome testing. D.S.H., A.M.R., and M.I. are unpaid scientific advisors of PathGen Diagnostik Teknologi. Other authors have no competing interest to declare.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Background: In Indonesia, early-onset colorectal cancer (EOCRC) rates are higher in patients <50 years old compared to western populations, possibly due to a higher frequency of Lynch Syndrome (LS) in CRC patients. We aim to examine the association of KRAS and PIK3CA mutation with LS.

Methods: In this cross-sectional study, the PCR-HRM-based test was used for screening of MSI mononucleotide markers (BAT25, BAT26, BCAT25, MYB, EWSR1), MLH1 promoter methylation, and oncogene mutations of BRAF(V600E), KRAS (exon 2 and 3), and PIK3CA (exon 9 and 20) in FFPE DNA samples.

Results: All the samples (n=244) were from Dr. Sardjito General Hospital Yogyakarta, Indonesia. KRAS and PIK3CA mutations were found in 151/244 (61.88%) and 107/244 (43.85%) of samples respectively. KRAS and PIK3CA mutations were significantly associated with MSI status in 32/42 (76.19%) and 25/42 (59.52%) of samples respectively. KRAS mutation was significantly associated with LS status in 26/32 (81.25%) of samples. The PIK3CA mutation was present in a higher proportion in LS samples of 19/32 (59.38%), but not statistically significant. Clinicopathology showed that KRAS mutation was significantly associated with right-sided CRC and higher histology grade in 39/151 (25.83%) and 24/151 (16.44%) samples respectively. PIK3CA mutation was significantly associated with female sex and lower levels of TILs in 62/107 (57.94%) and 26/107 (30.23%) samples respectively. KRAS and PIK3CA mutations did not significantly affect overall survival (120 months) in LS and non-LS patients.

Conclusions: High probability of LS in Indonesian CRC patients is associated with KRAS and PIK3CA mutations.

Keywords: Colorectal Neoplasms; Pathology, Molecular; Medical Oncology; Gastrointestinal Neoplasms; Neoplastic Syndromes, Hereditary

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION

Colorectal cancer (CRC) is the third most prevalent cancer worldwide and as well as one of the most deadly. Approximately in Indonesia, over 35,000 patients are diagnosed with CRC each year [1]. Three provinces in Indonesia have the highest incidence of CRC: Jakarta, Central Java, Yogyakarta. Early-onset colorectal cancer (EOCRC) accounts for nearly 30% of total CRC patients, three times higher than in Europe, the UK, and the USA [2]. The epidemiological data in Indonesia showed that the proportion of CRC patients <40 years old was more than 30% [3]. This incidence in Indonesia was higher in males (54%) than in females (46%), with a peak age of 50–54 years [2].

Lynch syndrome (LS) also known as hereditary non-polyposis colon cancer (HPNCC) is a hereditary type of CRC. This syndrome is characterized by early-onset (<50 years) [4, 5]. Our previous study introduced the higher frequency of LS cases in Yogyakarta, Indonesia which linked to a high risk of EOCRC [6].

Three molecular pathways have been identified for the pathogenesis of CRC: chromosomal instability (CIN), microsatellite instability (MSI), and the CpG Island Methylator Phenotype (CIMP) [7]. The CIN involves gene mutations in APC, KRAS, SMAD4, and TP53, while MSI is caused by mutations in Mismatch Repair (MMR) genes such as MSH2, MLH1, MSH3, PMS1, and PMS2 genes [8]. The CIMP, which is characterized by CG dinucleotide methylation in the promoters of numerous genes, is associated with distinct clinical and pathological attributes in tumors. These subtypes, as described by Jass Classification, include CIMP high/MSI high (12% of CRC), CIMP low/MSI low or microsatellite stable (20%), CIMP negative/microsatellite stable (57%), and Hereditary Non Polyposis Colorectal Cancer (HNPCC), with CIMP negative/MSI high and negative for BRAF mutations [7, 9-12]. Testing for MSI and MMR protein deficiency is commonly the first step in LS diagnostics due to germline mutations of MMR genes. On the contrary, epigenetic silencing of the MLH1 and somatic mutation of BRAF are common in sporadic tumors with MSI but very rarely occur in tumors arising in LS [13, 14].

KRAS mutations, the most common RAS family mutation, affect cell proliferation, differentiation, senescence, and apoptosis in 40% of sporadic CRC. These mutations increase CRC tumor aggressiveness, reduce survival rates, and promote treatment resistance [15]. Anti-EGFR monoclonal antibodies, such as cetuximab and panitumumab, are ineffective in CRC patients with KRAS codon 12, 13, or 14 mutations. Hence, these agents are only effective in RAS wild-type tumors [16]. BRAF mediates RAS-RAF-MAP kinase growth signal responses. BRAF mutations are found in 4% of MSI-low tumors and 40% of MSI-high tumors [17]. The most frequent of these mutations are $BRAF^{V600E}$ (Val600Glu). These $BRAF^{V600E}$ mutations help to differentiate between familial and sporadic CRC and are associated with poorer prognosis. Generally, BRAF mutations are confined to tumors without KRAS exon 2 mutations. BRAF is downstream of activated KRAS in the EGFR pathway, making cetuximab or panitumumab ineffective for inhibiting EGFR, unless given BRAF Inhibitor [10, 18].

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Phosphatidylinositol-3-kinase (PI3K) is a heterodimeric lipid kinase involved in cell signaling and cell membrane function. Mutations in PIK3CA have been reported in 10-20% of CRC cases [19]. PIK3CA mutations are associated with worse clinical outcomes and a negative predictor of response to anti-EGFR targeted therapy [20]. It has been shown that RAS mutations are negative predictors of anti-EGFR mAb response and survival benefit [20]. Over 80% of PIK3CA mutations are found in two hotspots: the helicase domain of exon 9 and the kinase domain in exon 20. Several studies have analyzed PIK3CA mutation in these hotspots for the discrepancy of the predictive values of PIK3CA as a biomarker for anti-EGFR [20, 21]. The PI3K pathway's downstream effectors include AKT and mTOR, which increase cell cycle regulator mRNA translation [22]. The decreased expression of tumor suppressor gene PTEN, a direct antagonist, has been shown to be correlated with poor outcomes in CRC [23].

In Indonesia, there has been limited investigation into the genetic mutation profiles of CRC patients, particularly those with LS. As reported in our previous study and others, several clinical features are associated with this syndrome, including tumor location of which 60-70% found in the right-sided (proximal) colon [6, 10]. In this study we examine the association of oncogenic mutations of KRAS and PIK3CA with MSI, MLH1 promoter methylation and LS as well as the demography and clinicopathology profile of CRC patients in Yogyakarta, Indonesia.

MATERIALS AND METHODS

Ethical Statements

This study was approved by the Medical and Health Research Ethics Committee (MHREC) Faculty of Medicine, Public Health, and Nursing of Universitas Gadjah Mada, Yogyakarta (Ethical Approval Number KE/FK/0837/EC/2022). The informed consents have been obtained for the use of tumor samples, clinical data and any other relevant data in the research for all subjects.

CRC Clinical Sample

For this observational cross-sectional study, we collected 288 CRC samples from the Department of Anatomic Pathology/Dr. Sardjito General Hospital Yogyakarta, Indonesia between 2016 and 2021. Of these, 244 formalin-fixed paraffin-embedded (FFPE) CRC samples were eligible for mutation detection. The patient data acquired for each case included sociodemographic (age and sex), tumor pathology (location/site, stage analysis, TNM stage, histologic grade, lymphatic status, morphology, tumor-infiltrating lymphocytes/TIL), and various clinical parameters (hemoglobin/Hb, albumin serum, Eastern Cooperative Oncology Group/ECOG scale, and body mass Index/BMI).

DNA Extraction

Paraffin blocks from colorectal cancer patients were cut into 6 pieces with 5 μm thickness. Only one piece in one slide continued with DNA extraction. Genomic DNA was extracted using the QIAamp DNA

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

FFPE tissue kit (Qiagen, USA) according to the manufacturer's protocol. DNA samples were quantified using a NanoDrop™ spectrophotometer (Thermo Scientific, Waltham, MA, USA). Samples of sufficient concentration and quality were adjusted to a concentration of 20 ng/µL for PCR applications.

Detection of MSI, BRAF, MLH1 and Oncogenes Mutation

All CRC biomarkers were detected using an IVD kit called BioColomelt-Dx manufactured by Biofarma Ltd, Indonesia. BioColomelt-Dx is a PCR-HRM molecular diagnostics kit for screening MSI, MLH1 promoter methylation, and important oncogene mutations of KRAS (exon 2 and 3), BRAF (V600E), PIK3CA (exon 9 and 20) in FFPE DNA samples. MSI, BRAF, MLH1 methylation promoter detections were previously described as N-LyST panel [24]. The N_LyST panel is a detection method for five mononucleotide microsatellite repeats, $BRAF^{V600E}$ mutations, and MLH1 region C promoter methylation status. For MSI analysis, samples were regarded as MSI if >2 markers (40%) showed instability; otherwise, they were regarded as MSS tumors. Samples showing MSI, BRAF wildtype, and MLH1 promoter methylation (unmethylated) were classified as “Probable Lynch”. Out of the total samples, 244 were successfully determined for oncogene mutation detection, while 223 were suitable for probable Lynch syndrome determination.

Statistical Analysis

Correlation between variables was calculated using Fisher's exact test with a significance level of $\alpha = 0.05$. All analysis was performed using R version 4.3.2.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

RESULTS

Association between KRAS and PIK3CA Mutation with MSI Status

The analysis of KRAS PIK3CA with MSI status is shown in Table 1. There was a significant association between mutated KRAS and MSI vs MSS (76.19% vs 58.91%; *P*-value=0.038, *P*-value<0.05); and mutated PIK3CA with MSI vs MSS (59.52% vs 40.59%; *P*-value=0.027, *P*-value<0.05). There were N=14/244 samples that had the concomitant mutation of KRAS and BRAF. There was no significant association between KRAS and BRAF concomitant mutation with MSI status (7.14% vs 5.45%; *P*-value= 0.7)

Association between KRAS and PIK3CA Mutation with Probable Lynch Status

The association of KRAS, PIK3CA and Lynch Status showed in Table 2. There was a significant association between mutated KRAS and probable Lynch status (81.25% vs 58.64%; *P*-value=0.018, *P*-value<0.05). However, there were no significant association between PIK3CA and Probable Lynch Status.

Clinicopathology Association with Oncogene Status

As shown in Table 3, PIK3CA gene mutation frequency was higher in female patients compared to the male patients (57.94% vs 42.06%; *P*-value=0.040, *P*-value<0.05). The lower level of TILs were found in mutated PIK3CA (30.23% vs 16.24%; *P*-value=0.021, *P*-value<0.05). The mutation rate of KRAS in the right sided was higher and statistically significant than the left sided (25.83% vs 13.04%; *P*-value=0.022, *P*-value<0.05). Mutant KRAS was significantly higher in Histology Grade 3 compared to wild-type KRAS (16.44% vs 7.53%; *P*-value=0.038, *P*-value<0.05). There was no significant association between other clinicopathology parameters with KRAS oncogene status.

Overall Survival on KRAS and PIK3CA Mutation Stratified by Lynch Syndrome Status

We analyzed the overall survival based on KRAS and PIK3CA mutations stratified by Lynch syndrome status. The number of samples that met the criteria for this analysis on PIK3CA and KRAS mutation are 220 and 222 samples, respectively. There were no statistically significant differences of overall survival (follow-up period of 120 month) based on KRAS and PIK3CA mutation with Probable Lynch and Non-Lynch status patient (Figure 1).

DISCUSSION

As molecular testing for colorectal cancer (CRC) is not routinely performed in clinical settings, currently there is only limited data on molecular landscape of CRC among the Indonesian patients. We previously reported higher incidence of early onset Colorectal Cancer (EOCRC) and probable Lynch Syndrome (LS) in our patient cohort from Yogyakarta, Indonesia [6]. In this study, we sought to examine

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

the association of oncogenic mutations of KRAS and PIK3CA, LS status and the clinicopathological features.

The frequency of KRAS mutations (exon 2 and exon 3) in our cohort reached 61.88%. This was much higher than what was reported in the Asia-Pacific (37-52%) and Western populations (32-49%) [25-38]. Nevertheless, our data is in line with a previous study in Indonesia, showing that KRAS mutation was found in 71.8% of serrated adenocarcinoma (SA), which is intriguingly higher than the generally reported incidence of 40% [39-41]. Another study, based on NGS (Next Generation Sequencing) analysis, showed that KRAS mutation occurred in 63.6% of 22 Indonesian patients with mostly advanced CRC [42]. Distinct mutations located in codons 13, 14, 34, 58, 59, and 146 were found as opposed to more commonly reported mutations in codons 12, 13, 61, 146 [42-44]. A recent study in China has also reported that KRAS mutation was found in 69.4% of the early lesions [45, 46].

Furthermore, in this study, we found that the KRAS mutation was enriched in MSI compared to MSS cases (76.19% and 58.91%, respectively). We previously reported a lower frequency of BRAF mutations (20.45%) in this MSI-CRC cohort [6], similar to what has been reported in China [47-49]. This is unlike a common dogma in which KRAS mutation is more associated with MSS while BRAF mutation is associated with MSI [50, 51]. We also observed the concomitant KRAS and BRAF mutation on 5.73% of total CRC cases. Despite previously thought as a rare event, there are growing number of studies reporting the co-mutation, this includes a study by Gong et al. (2017) showing the incidence rate of 1.4% of 138 metastatic CRC [52]. Our cohort was highly enriched for metastatic disease (41.1%) which may contribute to the higher frequency of co-mutation. To date, there is no optimal treatment for metastatic CRC harboring both KRAS and BRAF [53]. Consequently, our high co-mutation rate in the Indonesian population can shed new light that warrants further investigation. This study and others have shown that KRAS mutation was more frequent in right sided CRC [37, 54, 55]. The predilection of KRAS mutations for the right side of the colon may be influenced by the fact that the right and left side of the colon have different biology and histopathology in their respective embryological origins [37, 56, 57]. Right-sided CRC often has flat histopathology and a DNA mismatch repair pathway deficiency [58]. This may explain the significant association of mutated KRAS and MSI in our cohort.

Our study reports the PIK3CA (exon 9 and 20) mutation frequency of 43.85%, which is lower compared to a previous study in other regions of Indonesia with smaller sample size, reporting 70.9% mutation [59]. An NGS based study on Indonesian patients with advanced CRC revealed that all patients (100%, n=22) harboring PIK3CA mutation, distinctively in exon 2, 5, 7, 8, 10, 19, and 21, in addition to commonly reported exon 9 and 20 [42]. Similar to our result, a meta-analysis of 44 studies enrolling 17,621 patients has reported that mutations of PIK3CA exon 9 and 20 were associated with MSI, KRAS mutation and right-sided colon [60]. Tumor with MSI is usually associated with a high number of TILs due to the generation of neoantigens hence it serves as a good candidate for immunotherapy [61-63]. However, in

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

this study, we found a subset of lower numbers of TILs in PIK3CA-mutated cases, suggesting an immune-invading mechanism at play.

Interestingly, PD-L1 expression was correlated with PIK3CA mutations, suggesting that cancers with PIK3CA mutations and PD-L1 expression are immunotherapy candidates [64]. Inhibition of the PI3K-AKT pathway may improve effector T cell infiltration in PI3K-altered CRC. Combining PI3K inhibitors with anti-PD-1 could enhance treatment efficacy and CD8+ T cell proliferation [65]. It is also worth noting that PIK3CA mutations are prevalent in the early stages of MSI while it tends to occur later in MSS [66]. These suggest that the combination of PIK3CA mutation, MSI status, and PD-L1 expression could potentially be used to guide treatment selection or prognosis improvement for certain subsets of CRC patients.

As previously reported, our cohort was significantly enriched with EOCRC, defined as <50 years old [6]. We harnessed a robust, simple and affordable test called N_LyST to screen for probable LS, which fit into resource limited settings in Indonesia [24]. The test is a PCR (Polymerase Chain Reaction)-HRMA (High Resolution Melting Analysis) based method, consisting of 5 mononucleotide markers for MSI, MLH1 promoter methylation and BRAF V600E mutation in a single PCR run. We found that there was a high proportion of probable LS in our Indonesian CRC cohort (13.85%) and it was strongly associated with EOCRC, despite there still substantial numbers of EOCRC that were considered as non-LS/ sporadic cases [6].

Similar to other studies, this study found no significant association between oncogenic KRAS and PIK3CA mutations and EOCRC [67]. Nonetheless, in this study, we found high KRAS and PIK3CA mutations, 81.25% and 59.38% respectively, in patients with probable-LS status. These are much higher than previously reported in the literature, showing that KRAS mutations in the LS population ranging between 27-40% [68-72]. We have reported the positive association of PIK3CA mutation with KRAS mutation [73]. There was a statistically significant association between probable LS status and KRAS mutation, but not PIK3CA mutation. It has been reported in the literature that KRAS mutation was more frequently found in LS-related MSI CRC as compared to sporadic MSI CRC [69, 72, 74, 75]. On the other hand, PIK3CA mutation was reported to be more common in somatically mutated MMR-deficient CRC [76].

We observed no differences in overall patients' survival over a follow-up period of 120-months, between mutant and wildtype subgroups based on probable LS and non-LS/sporadic status for both KRAS and PIK3CA. Prior studies have shown that LS patients with CRC have a better prognosis than those with sporadic CRC, arguably due to its association with MSI and neoantigen generation in enhancing the immune response [77]. Although, as reported previously, we did not see this benefit of survival in our cohort [6]. It is appealing to speculate that high occurrences of KRAS mutation in our probable-LS patients outweigh the survival benefit of MSI. To our knowledge, there have been no studies yet that examine the association of survival rates in KRAS and PIK3CA mutations with LS in CRC.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Lynch syndrome is highly heterogeneous, showing high variability in age at onset (despite enriched in EOCRC), penetrance of cancer, and clinical presentations, which may be partly attributable to the molecular profiles of carcinomas. As reviewed by Helderman, et al. (2021), LS heterogeneity is attributable to a variety of different molecular pathways of tumor development, and only partly depends on which MMR gene is mutated [78]. It is now recognized that LS CRCs develop via one of three pathways. The first pathway is adenoma- carcinoma pathway, in which adenomas develop independently of MMR deficiency. The second and third pathway is MMR-deficient crypt foci (MMR-DCF)–Adenoma–Carcinoma pathway and MMR-DCF–Carcinoma pathway, which both start with MMR deficiency and is either followed by adenoma formation or results directly in a carcinoma [78, 79]. As widely known, APC mutations are more closely related to the development of adenomas, while CTNNB1 mutations appear to be associated with the MMR-DCF–Carcinoma pathway [74, 78].

Understanding the molecular landscape of LS, such as RAF/MEK/ERK and PI3K/PTEN/AKT signaling, will allow more detailed stratification of LS patients and will facilitate the provision of optimal care to each patient, including the diagnosis, surveillance, and treatment. For instance, activating PIK3CA variants are potentially susceptible to preventive aspirin therapy by inducing the transcription of COX2 gene increasing the production of PGE2 [74, 80]. This is in addition to known resistance of anti-EGFR of CRC harboring KRAS, BRAF and PIK3CA mutations [81, 82]. However, it is not yet known whether cancers that develop during aspirin therapy have a specific molecular signature [83].

In summary, despite the limitations of this study, including being conducted in a single center and utilizing a low throughput (PCR-based) workflow for mutation detections, this study has contributed to the better understanding of CRC molecular features in an underrepresented population in current global literatures. Our initial findings described in this paper and previous reports from our and other studies have indicated distinct genetic make-up such as high probability of LS, high frequency KRAS, and PIK3CA mutations, and lower BRAF mutation among CRC in Indonesia. This may underpin its unique clinical characteristics such as higher number of young patients and advanced disease stage. Further comprehensive multicenter analysis using high throughput techniques such as NGS is important to provide a more complete picture of the CRC carcinogenesis in Indonesia, with particular emphasis on EOCRC and LS. Understanding the global molecular landscape of CRC may reveal new knowledge that could challenge the current dogma, hence improving the effort to provide better care for the disease.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

CONCLUSION

The high probability of LS in Indonesian CRC patients is associated with KRAS and PIK3CA mutations. It improved our understanding of CRC molecular features in an underrepresented population in global literature.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Acknowledgments
The authors thank Aru W Sudoyo and Ahmad Utomo for critical input into study design and analysis of results, Yasjudan Rastrama Putra and Yana Suryani for technical assistance and coordination.

Financial Disclosures
MI was appointed as specialist committee member to the Diagnostics Assessment Committee of the National Institute for Health and Care Excellence (NICE), which produced the guidance DG27 on Lynch Syndrome testing. D.S.H., A.M.R., and M.I. are unpaid scientific advisors of PathGen Diagnostik Teknologi. Other authors have no competing interest to declare.

Conflict of Interest
MI was appointed as specialist committee member to the Diagnostics Assessment Committee of the National Institute for Health and Care Excellence (NICE), which produced the guidance DG27 on Lynch Syndrome testing. D.S.H., A.M.R., and M.I. are unpaid scientific advisors of PathGen Diagnostik Teknologi. Other authors have no competing interest to declare.

Informed Consent
All subjects provided written informed consent.

Author Contributions
Conception or design of the work: D.S.H., S.H.H., and S.S.;
Methodology: D.S.H., N.Y., G.A., A.M.R., and S.H.H.;
Software: G.A., H.H., M.Z.A., A.M.R., W.K.; and S.S.;
Validation: D.S.H., N.Y., G.A., A.M.R., S.H.H., and S.S.;
Formal Analysis: D.S.H., N.Y., G.A., H.H., M.Z.A., A.M.R., S.H.H., and S.S.;
Investigation: N.Y., G.A., H.H., A.M.R. W.K.; and S.S.;
Resources: D.S.H., N.Y., A.Y.H., J.K., S.H.H., and S.S.;
Data Curation: D.S.H., N.Y., G.A., V.L., H.H., Z.H., A.N.G., A.M.R, and S.S.;
Writing–Original Draft Preparation: D.S.H., V.L., H.H., Z.H., A.N.G., and S.S.;
Writing–Review and Editing: D.S.H., A.Y.H., M.I., J.K., S.H.H., and S.S.;
Visualization: G.A., M.Z.A., and S.S.;
Supervision: D.S.H., N.Y., M.I., S.H.H. and S.S.;
Project Administration: G.A., V.L., H.H., Z.H., and A.M.R.;
Funding Acquisition: D.S.H., M.I., S.H.H. and S.S.;
Approval of the version to be published: all authors. All authors have read and agreed to the published version of the manuscript.

Data Availability Statement
All data and related metadata underlying the findings reported in this manuscript have been provided as part of the submitted article. Any additional data that might support the findings of this study are available from the corresponding author, S.S., upon reasonable request.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Tables:

Table 1. KRAS and PIK3CA with MSI Mutational Status

Characteristic	MSI			
	Overall, N = 244[1]	**MSI,** N = 42[1]	**MSS,** N = 202[1]	***P*-value[2]**
KRAS				0.038*
Mutant	151 (61.88%)	32 (76.19%)	119 (58.91%)	
Wild-type	93 (38.11%	10 (23.81%)	83 (41.09%)	
KRAS CO BRAF				0.7
Yes	14 (5.73%)	3 (7.14%)	11 (5.45%)	
No	230 (94.26%)	39 (92.86%)	191 (94.55%)	
PIK3CA				0.027*
Mutant	107 (43.85%)	25 (59.52%)	82 (40.59%)	
Wild-type	137 (56.14%)	17 (40.48%)	120 (59.41%)	

[1]n (%)

[2]Fisher's exact test **P*-value<0.05; ***P*-value<0.01; ****P*-value<0.001

Table 2. KRAS, PIK3CA and Probable Lynch Status

Characteristic	Probable Lynch			
	Overall, N = 223[1]	**Yes,** N = 32[1]	**No,** N = 191[1]	***P*-value[2]**
KRAS				0.018*
Mutant	138 (61.88%)	26 (81.25%)	112 (58.64%)	
Wild-type	85 (38.12%)	6 (18.75%)	79 (41.36%)	
PIK3CA				0.13
Mutant	103 (46.19%)	19 (59.38%)	84 (43.98%)	
Wild-type	120 (53.81%)	13 (40.63%)	107 (56.02%)	

[1]n (%)

[2]Fisher's exact test **P*-value<0.05; ***P*-value<0.01; ****P*-value<0.001

Table 3. Clinicopathology Association with PIK3CA and KRAS Oncogene Status

Characteristic	Overall, N = 244[1]	PIK3CA			KRAS		
		Mutant, N = 107[1]	**Wild-type**, N = 137[1]	***P*-value[2]**	**Mutant**, N = 151[1]	**Wild-type**, N = 93[1]	***P*-value[2]**
Age				0.8			0.3
<50	53 (21.72%)	22 (20.56%)	31 (22.63%)		36 (23.84%)	17 (18.28%)	
>=50	191 (78.28%)	85 (79.44%)	106 (77.37%)		115 (76.16%)	76 (81.72%)	
Sex				0.040*			0.6
Female	123 (50.41%)	62 (57.94%)	61 (44.53%)		74 (49.01%)	49 (52.69%)	
Male	121 (49.59%)	45 (42.06%)	76 (55.47%)		77 (50.99%)	44 (47.31%)	
Tumor Site				0.083			0.022*
Left	192 (79.01%)	79 (73.83%)	113 (83.09%)		112 (74.17%)	80 (86.96%)	

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Right	51 (20.99%)	28 (26.17%)	23 (16.91%)		39 (25.83%)	12 (13.04%)	
Unknown	1	0	1		0	1	
Stage				0.6			>0.9
I	12 (5.08%)	5 (4.76%)	7 (5.34%)		7 (4.86%)	5 (5.43%)	
II	70 (29.66%)	33 (31.43%)	37 (28.24%)		43 (29.86%)	27 (29.35%)	
III	56 (23.73%)	28 (26.67%)	28 (21.37%)		35 (24.31%)	21 (22.83%)	
IV	98 (41.53%)	39 (37.14%)	59 (45.04%)		59 (40.97%)	39 (42.39%)	
Unknown	8	2	6		7	1	
T Status				>0.9			>0.9
1	3 (1.23%)	1 (0.94%)	2 (1.46%)		2 (1.33%)	1 (1.08%)	
2	25 (10.29%)	10 (9.43%)	15 (10.95%)		17 (11.33%)	8 (8.60%)	
3	156 (64.20%)	71 (66.98%)	85 (62.04%)		94 (62.67%)	62 (66.67%)	
4	59 (24.28%)	24 (22.64%)	35 (25.55%)		37 (24.67%)	22 (23.66%)	
Unknown	1	1	0		1	0	
N Status				0.3			0.7
0	121 (51.05%)	49 (46.67%)	72 (54.55%)		77 (53.10%)	44 (47.83%)	
1	84 (35.44%)	38 (36.19%)	46 (34.85%)		49 (33.79%)	35 (38.04%)	
2	32 (13.50%)	18 (17.14%)	14 (10.61%)		19 (13.10%)	13 (14.13%)	
Unknown	7	2	5		6	1	
Metastatic Status				0.3			0.8
0	139 (58.90%)	66 (62.86%)	73 (55.73%)		86 (59.72%)	53 (57.61%)	
1	97 (41.10%)	39 (37.14%)	58 (44.27%)		58 (40.28%)	39 (42.39%)	
Unknown	8	2	6		7	1	
Histological Grading				0.4			0.038*
1	107 (44.77%)	47 (45.19%)	60 (44.44%)		67 (45.89%)	40 (43.01%)	
2	99 (41.42%)	40 (38.46%)	59 (43.70%)		55 (37.67%)	44 (47.31%)	
3	31 (12.97%)	17 (16.35%)	14 (10.37%)		24 (16.44%)	7 (7.53%)	
4	2 (0.84%)	0 (0.00%)	2 (1.48%)		0 (0.00%)	2 (2.15%)	
Unknown	5	3	2		5	0	
Lymphovascular Status				0.3			>0.9
0	51 (46.36%)	27 (51.92%)	24 (41.38%)		29 (46.77%)	22 (45.83%)	
1	59 (53.64%)	25 (48.08%)	34 (58.62%)		33 (53.23%)	26 (54.17%)	
Unknown	134	55	79		89	45	
Pathological Morphology				0.2			0.7
Adeno-carcinoma	239 (97.95%)	103 (96.26%)	136 (99.27%)		147 (97.35%)	92 (98.92%)	
Mucinous Carcinoma	5 (2.05%)	4 (3.74%)	1 (0.73%)		4 (2.65%)	1 (1.08%)	
TILs				0.023*			0.6

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

High	80 (39.41%)	26 (30.23%)	54 (46.15%)		46 (36.80%)	34 (43.59%)	
Medium	78 (38.42%)	34 (39.53%)	44 (37.61%)		51 (40.80%)	27 (34.62%)	
Low	45 (22.17%)	26 (30.23%)	19 (16.24%)		28 (22.40%)	17 (21.79%)	
Unknown	41	21	20		26	15	
BMI (kg/m²)				0.3			0.081
<18,5	72 (30.77%)	33 (32.67%)	39 (29.32%)		42 (28.97%)	30 (33.71%)	
>=25	33 (14.10%)	18 (17.82%)	15 (11.28%)		18 (12.41%)	15 (16.85%)	
18,5-22,9	97 (41.45%)	36 (35.64%)	61 (45.86%)		69 (47.59%)	28 (31.46%)	
23-24,9	32 (13.68%)	14 (13.86%)	18 (13.53%)		16 (11.03%)	16 (17.98%)	
Unknown	10	6	4		6	4	
Hemoglobin level (g/dL)				>0.9			0.9
<10	48 (20.51%)	21 (20.59%)	27 (20.45%)		30 (21.13%)	18 (19.57%)	
>=10	186 (79.49%)	81 (79.41%)	105 (79.55%)		112 (78.87%)	74 (80.43%)	
Unknown	10	5	5		9	1	
ECOG		0.5			0.7		
0-1	154 (73.33%)	72 (75.79%)	82 (71.30%)		98 (75.38%)	56 (70.00%)	
2	38 (18.10%)	14 (14.74%)	24 (20.87%)		22 (16.92%)	16 (20.00%)	
3-4	18 (8.57%)	9 (9.47%)	9 (7.83%)		10 (7.69%)	8 (10.00%)	
Unknown	34	12	22		21	13	

[1]n (%)

[2]Fisher's exact test *P-value<0.05; **P-value<0.01; ***P-value<0.001

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figures:

Figure 1 Overall survival curves of CRC patients. A) Survival comparison on PIK3CA mutation and Probable Lynch status; B) Survival comparison on KRAS mutation and Probable Lynch status.



medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
2. Khairina D, Suzanna E, Triana D, Kadir A, Widyastuti TH, Sulistyowati LS, et al. Profile of Colorectal Cancer in 14 Provinces in Indonesia. Journal of Global Oncology. 2018;4(Supplement 2):66s-s.
3. Abdullah M, Meilany S, Trimarsanto H, Malik S, Sukartini N, Idrus F, et al. Genomic profiles of Indonesian colorectal cancer patients [version 2; peer review: 2 approved]. F1000Research. 2023;11(443).
4. Idos G and Laura V. Lynch Syndrome. GeneReviews®-NCBI Bookshelf. 2021. https://www.ncbi.nlm.nih.gov/books/NBK1211/
5. Bhattacharya P. Lynch Syndrome. StatPearls-NCBI Bookshelf. 2023.https://www.ncbi.nlm.nih.gov/books/NBK431096/.
6. Susanti S, Wibowo S, Akbariani G, Yoshuantari N, Heriyanto DS, Ridwanuloh AM, et al. Molecular Analysis of Colorectal Cancers Suggests a High Frequency of Lynch Syndrome in Indonesia. Cancers (Basel). 2021;13(24).
7. Singh MP, Rai S, Pandey A, Singh NK, Srivastava S. Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine. Genes & Diseases. 2021;8(2):133-45.
8. Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. Int J Mol Sci. 2020;22(1).
9. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113-30.
10. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res. 2012;5(1):19-27.
11. Ni Nyoman AD, Suksmarini NMPW, Pranata AANS, Rompis AY, Sumadi IWJ. The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali. Indonesian Journal of Biotechnology 2022;27(29).
12. Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol. 2012;27(9):1423-31.
13. Chen W, Frankel WL. A practical guide to biomarkers for the evaluation of colorectal cancer. Mod Pathol. 2019;32(Suppl 1):1-15.
14. Carnevali IW, Cini G, Libera L, Sahnane N, Facchi S, Viel A, et al. MLH1 Promoter Methylation Could Be the Second Hit in Lynch Syndrome Carcinogenesis. Genes (Basel). 2023;14(11).
15. Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021;20(1):143.
16. Yang G, Yu XR, Weisenberger DJ, Lu T, Liang G. A Multi-Omics Overview of Colorectal Cancer to Address Mechanisms of Disease, Metastasis, Patient Disparities and Outcomes. Cancers (Basel). 2023;15(11).
17. Meng M, Zhong K, Jiang T, Liu Z, Kwan HY, Su T. The current understanding on the impact of KRAS on colorectal cancer. Biomed Pharmacother. 2021;140:111717.
18. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. European Journal of Cancer. 2015;51(5):587-94.
19. Koveitypour Z, Panahi F, Vakilian M, Peymani M, Seyed Forootan F, Nasr Esfahani MH, et al. Signaling pathways involved in colorectal cancer progression. Cell Biosci. 2019;9:97.
20. Lu X, Li Y, Li Y, Zhang X, Shi J, Feng H, et al. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2023;23(1):1117.
21. Luo Q, Chen D, Fan X, Fu X, Ma T, Chen D. KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report. Transl Oncol. 2020;13(12):100874.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

22. Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74-88.
23. Mirzapour Abbas Abadi Z, Samiee Rad F, Hamedi Asl D, Rahmani B, Soleimani Dodaran M, Peimani A. Clinicopathological Significance of PTEN Expression and Its Prognostic Effect in Colorectal Adenocarcinoma Patients. Iran J Pathol. 2022;17(2):150-8.
24. Susanti S, Fadhil W, Ebili HO, Asiri A, Nestarenkaite A, Hadjimichael E, et al. N_LyST: a simple and rapid screening test for Lynch syndrome. J Clin Pathol. 2018;71(8):713-20.
25. Jeon SA, Ha YJ, Kim JH, Kim JH, Kim SK, Kim YS, et al. Genomic and transcriptomic analysis of Korean colorectal cancer patients. Genes Genomics. 2022;44(8):967-79.
26. Alkader MS, Altaha RZ, Badwan SA, Halalmeh AI, Al-Khawaldeh MH, Atmeh MT, et al. Impact of KRAS Mutation on Survival Outcome of Patients With Metastatic Colorectal Cancer in Jordan. Cureus. 2023;15(1):e33736.
27. Fu X, Huang Y, Fan X, Deng Y, Liu H, Zou H, et al. Demographic trends and KRAS/BRAF(V600E) mutations in colorectal cancer patients of South China: A single-site report. Int J Cancer. 2019;144(9):2109-17.
28. Loong HH, Du N, Cheng C, Lin H, Guo J, Lin G, et al. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Transl Lung Cancer Res. 2020;9(5):1759-69.
29. Wong H-l, Cui W, Loft M, Lee M, Wong R, Shapiro J, et al. Assessing real-world outcomes in metastatic colorectal cancer with KRAS G12C mutation. Journal of Clinical Oncology. 2020;38:e16072-e.
30. El Agy F, El Bardai S, El Otmani I, Benbrahim Z, Karim IMH, Mazaz K, et al. Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report. PloS one [Internet]. 2021 2021; 16(3):[e0248522 p.]. Available from: http://europepmc.org/abstract/MED/33784337
31. Radanova M, Mihaylova G, Stoyanov GS, Draganova V, Zlatarov A, Kolev N, et al. KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer. Int J Mol Sci. 2023;24(16).
32. Sanchez-Ibarra HE, Jiang X, Gallegos-Gonzalez EY, Cavazos-González AC, Chen Y, Morcos F, et al. KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study. PLoS One. 2020;15(7):e0235490.
33. Turpin A, Genin M, Hebbar M, Occelli F, Lanier C, Vasseur F, et al. Spatial heterogeneity of KRAS mutations in colorectal cancers in northern France. Cancer Manag Res. 2019;11:8337-44.
34. Araujo LH, Souza BM, Leite LR, Parma SAF, Lopes NP, Malta FSV, et al. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer. BMC Cancer. 2021;21(1):193.
35. Gvaldin DY, Kit OI, Omelchuk EP, Kaymakchi DO, Poluektov SI, Petrov DS, et al. Frequency of somatic mutations in the KRAS gene in patients of the South Russia diagnosed with colorectal cancer. Journal of Clinical Oncology. 2019.
36. Maus MK, Grimminger PP, Mack PC, Astrow SH, Stephens C, Zeger G, et al. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. Lung Cancer. 2014;83(2):163-7.
37. Alghamdi M, Alabdullatif N, Al-Rashoud A, Alotaibi J, Alhussaini N, Elsirawani S, et al. KRAS Mutations in Colorectal Cancer: Relationship With Clinicopathological Characteristics and Impact on Clinical Outcomes in Saudi Arabia. Cureus. 2022;14(3):e23656.
38. Yang Q, Huo S, Sui Y, Du Z, Zhao H, Liu Y, et al. Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers. Front Oncol. 2018;8:487.
39. Nur R, Diah RH, Marini S, Ening K. The low prevalence of colonic serrated adenocarcinoma with high KRAS mutational status at Cipto Mangunkusumo Hospital, Indonesia. Medical Journal of Indonesia. 2018;27(3).

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

40. Stefanius K, Ylitalo L, Tuomisto A, Kuivila R, Kantola T, Sirniö P, et al. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology. 2011;58:679-92.
41. García-Solano J, Conesa-Zamora P, Carbonell P, Trujillo-Santos J, Torres-Moreno DD, Pagán-Gómez I, et al. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. Int J Cancer. 2012;131(8):1790-9.
42. Marbun VMG, Erlina L, Lalisang TJM. Genomic landscape of pathogenic mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian colorectal cancer. PLOS ONE. 2022;17(6):e0267090.
43. He K, Wang Y, Zhong Y, Pan X, Si L, Lu J. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. Onco Targets Ther. 2020;13:12601-13.
44. Heuvelings DJI, Wintjens A, Luyten J, Wilmink G, Moonen L, Speel EM, et al. DNA and RNA Alterations Associated with Colorectal Peritoneal Metastases: A Systematic Review. Cancers (Basel). 2023;15(2).
45. Li Y, Xiao J, Zhang T, Zheng Y, Jin H. Analysis of KRAS, NRAS, and BRAF Mutations, Microsatellite Instability, and Relevant Prognosis Effects in Patients With Early Colorectal Cancer: A Cohort Study in East Asia. Front Oncol. 2022;12:897548.
46. Chang XN, Shang FM, Jiang HY, Chen C, Zhao ZY, Deng SH, et al. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China. Curr Med Sci. 2021;41(1):118-26.
47. Mei WJ, Mi M, Qian J, Xiao N, Yuan Y, Ding PR. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: A narrative review. Front Immunol. 2022;13:1019582.
48. Ye ZL, Qiu MZ, Tang T, Wang F, Zhou YX, Lei MJ, et al. Gene mutation profiling in Chinese colorectal cancer patients and its association with clinicopathological characteristics and prognosis. Cancer Med. 2020;9(2):745-56.
49. Ye JX, Liu Y, Qin Y, Zhong HH, Yi WN, Shi XY. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol. 2015;21(5):1595-605.
50. Molina-Cerrillo J, San Román M, Pozas J, Alonso-Gordoa T, Pozas M, Conde E, et al. BRAF Mutated Colorectal Cancer: New Treatment Approaches. Cancers (Basel). 2020;12(6).
51. Kassem NM, Emera G, Kassem HA, Medhat N, Nagdy B, Tareq M, et al. Clinicopathological features of Egyptian colorectal cancer patients regarding somatic genetic mutations especially in KRAS gene and microsatellite instability status: a pilot study. Egyptian Journal of Medical Human Genetics. 2019;20(1):20.
52. Gong J, Cho M, Sy M, Salgia R, Fakih M. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget. 2017;8(26):42198-213.
53. Midthun L, Shaheen S, Deisch J, Senthil M, Tsai J, Hsueh CT. Concomitant KRAS and BRAF mutations in colorectal cancer. J Gastrointest Oncol. 2019;10(3):577-81.
54. Xie M-z, Li J-l, Cai Z-m, Li K-z, Hu B-l. Impact of primary colorectal Cancer location on the KRAS status and its prognostic value. BMC Gastroenterology. 2019;19(1):46.
55. Bonnot PE, Passot G. RAS mutation: site of disease and recurrence pattern in colorectal cancer. Chin Clin Oncol. 2019;8(5):55.
56. Pîrvu EE, Severin E, Pătru RI, Niță I, Toma SA, Macarie RR, et al. Correlations between Demographic, Clinical, and Paraclinical Variables and Outcomes in Patients with KRAS-Mutant or KRAS Wild-Type Metastatic Colorectal Cancer—A Retrospective Study from a Tertiary-Level Center in Romania. Diagnostics. 2023;13(18):2930.
57. Oliveira-Silveira J, Filippi-Chiela E, Saffi J. Laterality influence on gene expression of DNA damage repair in colorectal cancer. Scientific Reports. 2023;13(1):15963.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

58. Baran B, Mert Ozupek N, Yerli Tetik N, Acar E, Bekcioglu O, Baskin Y. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. Gastroenterology Res. 2018;11(4):264-73.
59. Labeda I, Syarifuddin E, Uwuratuw J, Pattelongi I, Faruk M. Analysis of PIK3CA expression to clinicopathology features of colorectal cancer in Makassar, Indonesia. International Journal of Surgery and Medicine. 2020;6:48-52.
60. Jin J, Shi Y, Zhang S, Yang S. PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis. Acta Oncol. 2020;59(1):66-74.
61. Westdorp H, Fennemann FL, Weren RD, Bisseling TM, Ligtenberg MJ, Figdor CG, et al. Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother. 2016;65(10):1249-59.
62. Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Front Immunol. 2020;11:369.
63. Koury J, Lucero M, Cato C, Chang L, Geiger J, Henry D, et al. Immunotherapies: Exploiting the Immune System for Cancer Treatment. J Immunol Res. 2018;2018:9585614.
64. Ahn AR, Kim KM, Jang KY, Moon WS, Ha GW, Lee MR, et al. Correlation of PIK3CA mutation with programmed death ligand-1 (PD-L1) expression and their clinicopathological significance in colorectal cancer. Ann Transl Med. 2021;9(18):1406.
65. Nusrat M, Syed MA, Katkhuda R, Parra ER, Wistuba II, Kong P, et al. The immune impact of PI3K-AKT pathway inhibition in colorectal cancer. Journal of Clinical Oncology. 2022;40(4_suppl):154-.
66. Li W, Qiu T, Dong L, Zhang F, Guo L, Ying J. Prevalence and characteristics of PIK3CA mutation in mismatch repair-deficient colorectal cancer. J Cancer. 2020;11(13):3827-33.
67. Hamilton AC, Bannon FJ, Dunne PD, James J, McQuaid S, Gray RT et al. Distinct molecular profiles of sporadic early onset colorectal cancer: a population-based cohort and systematic review. Gastro Hep Advances. 2023 Mar 1;2(3):347-359
68. Garre P, Martín L, Bando I, Tosar A, Llovet P, Sanz J, et al. Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer. Fam Cancer. 2014;13(1):109-19.
69. Li W, Zhi W, Zou S, Qiu T, Ling Y, Shan L, et al. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. PLoS One. 2015;10(6):e0128202.
70. Abdel-Rahman WM, Ollikainen M, Kariola R, Järvinen HJ, Mecklin JP, Nyström-Lahti M, et al. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene. 2005;24(9):1542-51.
71. Goel A, Xicola RM, Nguyen TP, Doyle BJ, Sohn VR, Bandipalliam P, et al. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology. 2010;138(5):1854-62.
72. Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet. 2004;13(19):2303-11.
73. Susanti S, Fadhil W, Murtaza S, Hassall JC, Ebili HO, Oniscu A, et al. Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific. J Clin Pathol. 2019;72(3):263-4.
74. Ahadova A, Gallon R, Gebert J, Ballhausen A, Endris V, Kirchner M, et al. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. Int J Cancer. 2018;143(1):139-50.
75. Ten Broeke SW, van der Klift HM, Tops CMJ, Aretz S, Bernstein I, Buchanan DD, et al. Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol. 2018;36(29):2961-8.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.03.24303469; this version posted March 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

76. Cohen SA, Turner EH, Beightol MB, Jacobson A, Gooley TA, Salipante SJ, et al. Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. Gastroenterology. 2016;151(3):440-7.e1.
77. Battaglin F, Naseem M, Lenz HJ, Salem ME. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 2018;16(11):735-45.
78. Helderman NC, Bajwa-Ten Broeke SW, Morreau H, Suerink M, Terlouw D, van der Werf TLAS, et al. The diverse molecular profiles of lynch syndrome-associated colorectal cancers are (highly) dependent on underlying germline mismatch repair mutations. Crit Rev Oncol Hematol. 2021;163:103338.
79. Lepore Signorile M, Disciglio V, Di Carlo G, Pisani A, Simone C, Ingravallo G. From Genetics to Histomolecular Characterization: An Insight into Colorectal Carcinogenesis in Lynch Syndrome. International Journal of Molecular Sciences. 2021;22(13):6767.
80. Wang D, Fu L, Sun H, Guo L, DuBois RN. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology. 2015;149(7):1884-95.e4.
81. Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget. 2017;8(3):3980-4000.
82. Li ZN, Zhao L, Yu LF, Wei MJ. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep (Oxf). 2020;8(3):192-205.
83. Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395(10240):1855-63.

A)


Survival probability
1.00
0.75
0.50
0.25
0.00
p = 0.84
0
24
48
72
96
120
Time by Months
PIK3CA Mutant-Probable Lynch
PIK3CA Mutant-Sporadic
PIK3CA Wild type-Probable Lynch
PIK3CA Wild type-Sporadic
Number at risk
PIK3CA Mutant-Probable Lynch 19 15 13 6 2 1
PIK3CA Mutant-Sporadic 82 68 52 16 1 0
PIK3CA Wild type-Probable Lynch 12 9 7 4 0 0
PIK3CA Wild type-Sporadic 107 93 69 28 6 0
0 24 48 72 96 120
Time by Months

B)


Survival probability
1.00
0.75
0.50
0.25
0.00
p = 0.9
0
24
48
72
96
120
Time by Months
KRAS Mutant-Probable Lynch
KRAS Mutant-Sporadic
KRAS Wild type-Probable Lynch
KRAS Wild type-Sporadic
Number at risk
KRAS Mutant-Probable Lynch 25 19 17 9 2 1
KRAS Mutant-Sporadic 111 96 75 30 3 0
KRAS Wild type-Probable Lynch 6 5 3 1 0 0
KRAS Wild type-Sporadic 80 67 48 16 5 1
0 24 48 72 96 120
Time by Months